Dipartmento di Sanità Pubblica, Azienda USL di Bologna, Italy.
Dipartmento di Sanità Pubblica, Azienda USL di Bologna, Italy and Facoltà di Scienze Statistiche, University of Bologna .
Acta Biomed. 2021 Sep 2;92(4):e2021270. doi: 10.23750/abm.v92i4.11896.
Randomized controlled trials have shown that mRNA vaccines are highly effective in preventing SARS-CoV2 infection. We conducted a study to assess the real-world effectiveness of mRNA vaccines (Pfizer-BioNTech or Moderna) in preventing all and symptomatic SARS-CoV2 infections and COVID-19 related hospitalizations in the staff of the Bologna Health Trust (HT), Italy Methods: We followed up retrospectively 9839 staff of the Bologna HT from December 27, 2020 to April 3, 2020 and calculated the effectiveness in partially and fully vaccinated subjects by applying a multivariable Cox proportional hazard model.
Vaccine effectiveness in preventing SARS-CoV2 infections is 85.5% (95%CI: 75.9-91.3) in the partially vaccinated and 84.8% (95%CI: 73.2-91.4) in the fully vaccinated. In preventing symptomatic infection effectiveness is 81.7% (95%CI: 62.7-91.0) in the partially and 87.1% (95%CI: 69.3-94.6) in the fully vaccinated. There were no COVID-19-related hospitalizations in the partially or fully vaccinated vs 15 hospitalization in the unvaccinated cohort.
Our results confirm the effectiveness of mRNA vaccines in a real-world setting in Northern Italy.
随机对照试验表明，mRNA 疫苗在预防 SARS-CoV2 感染方面具有高度有效性。我们进行了一项研究，以评估 mRNA 疫苗（辉瑞-生物科技或 Moderna）在预防博洛尼亚卫生信托（HT）意大利工作人员中所有和有症状的 SARS-CoV2 感染以及与 COVID-19 相关的住院方面的真实世界效果。
我们对 2020 年 12 月 27 日至 2020 年 4 月 3 日期间博洛尼亚 HT 的 9839 名工作人员进行了回顾性随访，并通过多变量 Cox 比例风险模型计算了部分和完全接种疫苗者的有效性。
在部分接种疫苗者中，疫苗预防 SARS-CoV2 感染的有效性为 85.5%（95%CI：75.9-91.3），在完全接种疫苗者中为 84.8%（95%CI：73.2-91.4）。在预防有症状感染方面，部分接种疫苗者的有效性为 81.7%（95%CI：62.7-91.0），完全接种疫苗者的有效性为 87.1%（95%CI：69.3-94.6）。部分或完全接种疫苗者中无 COVID-19 相关住院治疗，而未接种疫苗者中有 15 例住院治疗。
我们的结果在意大利北部的真实环境中证实了 mRNA 疫苗的有效性。
